Join
Live feed
·
INSIDERFilingvia Quantisnow
Allogene Therapeutics Inc. logo

SVP, General Counsel Douglas Earl Martin sold $62,958 worth of shares (29,697 units at $2.12), decreasing direct ownership by 6% to 488,267 units (SEC Form 4) to satisfy withholding obligation

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALLO (Allogene Therapeutics Inc.) and more on Quantisnow.